PMID- 31668143
OWN - NLM
STAT- MEDLINE
DCOM- 20210319
LR  - 20210319
IS  - 1840-4812 (Electronic)
IS  - 1512-8601 (Print)
IS  - 1512-8601 (Linking)
VI  - 20
IP  - 2
DP  - 2020 May 1
TI  - The efficacy and safety of statin in combination with ezetimibe compared with 
      double-dose statin in patients with high cardiovascular risk: A meta-analysis.
PG  - 169-182
LID - 10.17305/bjbms.2019.4437 [doi]
AB  - Currently, statins are the first-line therapies for dyslipidemia and 
      atherosclerotic cardiovascular disease, however, their hypolipidemic effects have 
      not been satisfactory. We performed a meta-analysis to compare lipid-lowering 
      efficacy and safety of ezetimibe and statin combination therapy with double-dose 
      statin monotherapy in patients with high cardiovascular risk. Fourteen studies 
      involving 3105 participants were included in the final analysis; 1558 (50.18%) 
      participants received ezetimibe and statin combination therapy and 1547 (49.82%) 
      received double-dose statin monotherapy. Eight studies reported the percentages 
      of changes in several lipid parameters from baseline to endpoint in both groups. 
      Lipid parameters changed more significantly in patients coadministered with 
      ezetimibe and statin (low-density lipoprotein cholesterol [LDL-C]: MD = -9.39, 
      95% CI -13.36 to -5.42; non-high-density lipoprotein cholesterol [non-HDL-C]: MD 
      = -10.36, 95% CI -14.23 to -6.50; total cholesterol [TC]: MD = -8.11, 95% CI 
      -10.95 to -5.26; and triglyceride [TG]: MD = -5.96, 95% CI -9.12 to -2.80), with 
      moderate to high heterogeneity among the studies. Two out of fourteen studies 
      investigated several different statins. Our subgroup analysis showed that, 
      compared with double-dose atorvastatin monotherapy, ezetimibe and atorvastatin 
      combination therapy significantly decreased LDL-C, non-HDL-C, TC, and TG levels 
      by 14.16%, 14.01%, 11.06%, and 5.96%, respectively (p < 0.001). No significant 
      difference was found in the incidence of laboratory-related adverse events (AEs) 
      between statin combination therapy and monotherapy. Overall, ezetimibe and statin 
      combination therapy significantly decreased LDL-C, non-HDL-C, and TC levels in 
      patients with high cardiovascular risk, among which ezetimibe combined with 
      atorvastatin had the best therapeutic effect. Compared with ezetimibe and statin 
      combination therapy, double-dose statin monotherapy did not increase the risk of 
      AEs.
FAU - Zhu, Yunyun
AU  - Zhu Y
AD  - Geriatrics Department, Ningbo First Hospital, Zhejiang, China.
FAU - Hu, Haochang
AU  - Hu H
AD  - Cardiovascular Department, Ningbo First Hospital, Zhejiang, China. h.
FAU - Yang, Jun
AU  - Yang J
AD  - Geriatrics Department, Ningbo First Hospital, Zhejiang, China.
FAU - Yao, Qi
AU  - Yao Q
AD  - Geriatrics Department, Ningbo First Hospital, Zhejiang, China.
FAU - Xu, Hongyu
AU  - Xu H
AD  - Geriatrics Department, Ningbo First Hospital, Zhejiang, China.
FAU - Yu, Yushan
AU  - Yu Y
AD  - Geriatrics Department, Ningbo First Hospital, Zhejiang, China.
FAU - Liu, Ting
AU  - Liu T
AD  - Geriatrics Department, Ningbo First Hospital, Zhejiang, China.
FAU - Lin, Shaoyi
AU  - Lin S
AD  - Cardiovascular Department, Ningbo First Hospital, Zhejiang, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20200501
PL  - Bosnia and Herzegovina
TA  - Bosn J Basic Med Sci
JT  - Bosnian journal of basic medical sciences
JID - 101200947
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - EOR26LQQ24 (Ezetimibe)
SB  - IM
MH  - Cardiovascular Diseases/etiology/*prevention & control
MH  - Drug Therapy, Combination
MH  - Ezetimibe/*administration & dosage
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*administration & dosage
PMC - PMC7202188
COIS- Conflict of interest statement: The authors declare no conflict of interests
EDAT- 2019/11/02 06:00
MHDA- 2021/03/20 06:00
PMCR- 2020/05/01
CRDT- 2019/11/01 06:00
PHST- 2019/09/02 00:00 [received]
PHST- 2019/10/06 00:00 [accepted]
PHST- 2019/11/02 06:00 [pubmed]
PHST- 2021/03/20 06:00 [medline]
PHST- 2019/11/01 06:00 [entrez]
PHST- 2020/05/01 00:00 [pmc-release]
AID - BJBMS-20-169 [pii]
AID - 10.17305/bjbms.2019.4437 [doi]
PST - epublish
SO  - Bosn J Basic Med Sci. 2020 May 1;20(2):169-182. doi: 10.17305/bjbms.2019.4437.